



## Antifibrotic Drugs

Guest Editor:

**Prof. Dr. Peter Olinga**

Department of Pharmaceutical  
Technology and Biopharmacy,  
University of Groningen, 9713 AV  
Groningen, The Netherlands

Deadline for manuscript  
submissions:

**closed (15 December 2019)**

### Message from the Guest Editor

Dear Colleagues,

Fibrosis is an exaggerated wound-healing response to chronic tissue damage. Fibrosis affects nearly all tissues and organ systems and ultimately results in organ failure. Diseases leading to fibrosis are an increasing clinical and economic burden. It is estimated that fibrosis contributes to almost 45% of deaths in the developed world, as this pathology is a feature of numerous conditions (e.g., persistent viral infections and autoimmune reactions) across multiple organs. Despite the progress made in the field of fibrosis research, the clinical success rate in antifibrotic drug development is very limited. Therefore, this Special Issue will discuss promising new targets to treat organ fibrosis and potential antifibrotic drugs. Furthermore, there will be an emphasis on targeted delivery and formulation of potential antifibrotic drugs. Animal models of fibrosis rarely predict the success of antifibrotic drugs in humans. Hence, this issue will deliberate novel models that better predict the efficacy of antifibrotic drug in humans.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Ernest Mario School of  
Pharmacy, Rutgers, The State  
University of New Jersey, William  
Levine Hall, Room 225C, 160  
Frelinghuysen Road, Piscataway,  
NJ 08854-8020, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceutics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma